BFC Planning’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$277K Buy
+173,000
New +$329K 0.01% 817
2026
Q2
– Sell
-288,000
Closed -$703K – 3428
2026
Q1
$703K Sell
288,000
-64,500
-18% -$129K 0.03% 460
2025
Q4
$483K Buy
352,500
+352,249
+140,338% +$465K 0.02% 563
2025
Q3
$311 Hold
251
– – ﹤0.01% 2794
2025
Q2
$284 Buy
+251
New +$334 ﹤0.01% 2588

Other funds holding ALLO

BFC Planning's ALLO Position: Q3 2026 in Review

BFC Planning opened a new position in Allogene Therapeutics (ALLO) in Q3 2026: 173,000 shares worth $277K. The stake represents 0.01% of the portfolio and ranks #817 among its holdings. This is a return to the name: BFC Planning previously reported a position in ALLO as recently as Q1 2026.

BFC Planning first reported a position in ALLO in Q2 2025 and has held it in 5 quarters since. The position peaked at $703K in Q1 2026. 141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • BFC Planning held 173,000 shares of Allogene Therapeutics worth $277K as of Q3 2026.
  • Allogene Therapeutics was a new BFC Planning position in Q3 2026.
  • Allogene Therapeutics made up 0.01% of BFC Planning's portfolio in Q3 2026, its #817 holding.
  • BFC Planning first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • BFC Planning's Allogene Therapeutics position peaked at $703K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.